{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:02:04Z","timestamp":1791090124393,"version":"4.1.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Geographic atrophy (GA) is a complication of advanced neovascular age-related macular degeneration that can lead to permanent vision loss. We sought to estimate the incidence and progression of GA after intravitreal injections of antivascular endothelial growth factor agents in eyes with neovascular age-related macular degeneration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Ovid MEDLINE, EMBASE, and Cochrane CENTRAL were searched from inception to May 2020. Included studies reported on the progression or development of GA in eyes with neovascular age-related macular degeneration after antivascular endothelial growth factor therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Thirty-one articles and 4,609 study eyes (4,501 patients) were included. Eyes received a mean of 17.7 injections over 35.2 months. The prevalence of GA at baseline was 9.7%. The pooled incidence of GA was 30.5% at the end of follow-up. There was a positive, moderate linear correlation between the mean total number of injections and GA incidence at the final follow-up (R\n                      <jats:sup>2<\/jats:sup>\n                      = 0.30;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.01). Monthly treatment was associated with a significantly higher risk for GA development relative to pro re nata (relative risk = 1.40, 95% confidence interval = [1.21\u20131.61],\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). Risk factors for GA development included GA in the fellow eye, retinal angiomatous proliferation, drusen, and reticular pseudodrusen.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>We found an association between the frequency and number of treatments with antivascular endothelial growth factor agents and the development of GA in neovascular age-related macular degeneration. Future studies should clarify risk factors, population characteristics, and relative contributions of treatment and disease progression on GA development in this context.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000003207","type":"journal-article","created":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T16:03:09Z","timestamp":1623168189000},"page":"2424-2435","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":23,"title":["GEOGRAPHIC ATROPHY INCIDENCE AND PROGRESSION AFTER INTRAVITREAL INJECTIONS OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS FOR AGE-RELATED MACULAR DEGENERATION"],"prefix":"10.1097","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0047-8157","authenticated-orcid":false,"given":"Arshia","family":"Eshtiaghi","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam","family":"Issa","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko M.","family":"Popovic","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev H.","family":"Muni","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada;"},{"name":"Department of Ophthalmology, St. Michael's Hospital\/Unity Health Toronto, Toronto, Ontario, Canada; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Kertes","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada;"},{"name":"John and Liz Tory Eye Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250607","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.2146\/ajhp070342","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"65","author":"Hernandez-Pastor","year":"2008","journal-title":"Am J Heal Pharm"},{"key":"R2-20250607","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Martin","year":"2011","journal-title":"N Engl J Med"},{"key":"R3-20250607","article-title":"Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature","author":"Falavarjani","year":"2013","journal-title":"Eye"},{"key":"R4-20250607","doi-asserted-by":"crossref","DOI":"10.1016\/S0161-6420(99)90340-8","article-title":"Enlargement of atrophy and visual acuity loss in the geographic atrophy form of age-related macular degeneration","author":"Sunness","year":"1999","journal-title":"Ophthalmology"},{"key":"R5-20250607","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ophtha.2018.07.013","article-title":"Intralesional macular atrophy in anti\u2013vascular endothelial growth factor therapy for age-related macular degeneration in the IVAN trial","volume":"126","author":"Bailey","year":"2019","journal-title":"Ophthalmology"},{"key":"R6-20250607","doi-asserted-by":"crossref","DOI":"10.1016\/j.oret.2016.09.005","article-title":"Evolution of geographic atrophy in participants treated with ranibizumab for neovascular age-related macular degeneration","author":"Thavikulwat","year":"2017","journal-title":"Ophthalmol Retina"},{"key":"R7-20250607","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1097\/IAE.0000000000001059","article-title":"Progression of macular atrophy in patients with neovascular age-related macular degeneration undergoing antivascular endothelial growth factor therapy","volume":"36","author":"Abdelfattah","year":"2016","journal-title":"Retina"},{"key":"R8-20250607","doi-asserted-by":"crossref","DOI":"10.1038\/eye.2016.208","article-title":"Risk of geographic atrophy in age-related macular degeneration patients treated with intravitreal anti-VEGF agents","author":"Gemenetzi","year":"2017","journal-title":"Eye"},{"key":"R9-20250607","doi-asserted-by":"crossref","DOI":"10.1097\/IAE.0000000000000374","article-title":"Geographic atrophy in patients receiving anti-vascular endothelial growth factor for neovascular age-related macular degeneration","author":"Xu","year":"2015","journal-title":"Retina"},{"key":"R10-20250607","doi-asserted-by":"crossref","DOI":"10.4274\/tjo.27448","article-title":"Is there a relationship between use of anti-vascular endothelial growth factor agents and atrophic changes in age-related macular degeneration patients?","author":"Kaynak","year":"2018","journal-title":"Turkish J Ophthalmol"},{"key":"R11-20250607","doi-asserted-by":"crossref","DOI":"10.1097\/IAE.0000000000001392","article-title":"The pathophysiology of geographic atrophy secondary to age-related macular degeneration and the complement pathway as a therapeutic target","author":"Boyer","year":"2017","journal-title":"Retina"},{"key":"R12-20250607","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2019.11.016","article-title":"Incidence of macular atrophy after untreated neovascular age-related macular degeneration: age-related eye disease study report 40","author":"Christakis","year":"2020","journal-title":"Ophthalmology"},{"key":"R13-20250607","doi-asserted-by":"crossref","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","author":"Hayden","year":"2013","journal-title":"Ann Intern Med"},{"key":"R14-20250607","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"R15-20250607","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2013.08.015","article-title":"Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials","author":"Grunwald","year":"2014","journal-title":"Ophthalmology"},{"key":"R16-20250607","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta19780","article-title":"A randomised controlled trial to assess the clinical effectiveness and cost-effectiveness of alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN)","volume":"19","author":"Chakravarthy","year":"2015","journal-title":"Health Technol Assess"},{"key":"R17-20250607","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.ophtha.2017.12.026","article-title":"Macular atrophy in the HARBOR study for neovascular age-related macular degeneration","volume":"125","author":"Sadda","year":"2018","journal-title":"Ophthalmology"},{"key":"R18-20250607","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2006.10.040","article-title":"Fifteen-year cumulative incidence of age-related macular degeneration. The beaver Dam eye study","author":"Klein","year":"2007","journal-title":"Ophthalmology"},{"key":"R19-20250607","doi-asserted-by":"crossref","DOI":"10.1186\/s12886-017-0544-x","article-title":"Predictive models of long-term anatomic outcome in age-related macular degeneration treated with as-needed Ranibizumab","author":"Gonzalez-Buendia","year":"2017","journal-title":"BMC Ophthalmol"},{"key":"R20-20250607","doi-asserted-by":"crossref","first-page":"e757","DOI":"10.1111\/aos.13157","article-title":"Macular atrophy in patients with long-term anti-VEGF treatment for neovascular age-related macular degeneration","volume":"94","author":"Munk","year":"2016","journal-title":"Acta Ophthalmol"},{"key":"R21-20250607","doi-asserted-by":"crossref","first-page":"285.e1","DOI":"10.1016\/j.ajo.2014.10.035","article-title":"Risk factors for geographic atrophy after intravitreal ranibizumab injections for retinal angiomatous proliferation","volume":"159","author":"Cho","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"R22-20250607","doi-asserted-by":"crossref","DOI":"10.1097\/IAE.0000000000002054","article-title":"Macular atrophy incidence in anti-vascular endothelial growth factor-treated neovascular age-related macular degeneration: risk factor evaluation for individualized treatment need of ranibizumab or aflibercept according to an observe-and-plan regimen","author":"Mantel","year":"2019","journal-title":"Retina"},{"key":"R23-20250607","doi-asserted-by":"crossref","DOI":"10.1159\/000492924","article-title":"Onset of retinal pigment epithelium atrophy subsequent to anti-VEGF therapy in patients with neovascular age-related macular degeneration","author":"Sitnilska","year":"2019","journal-title":"Ophthalmologica"},{"key":"R24-20250607","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s10384-016-0478-5","article-title":"Efficacy of intravitreal aflibercept in Japanese patients with exudative age-related macular degeneration","volume":"61","author":"Saito","year":"2017","journal-title":"Jpn J Ophthalmol"},{"key":"R25-20250607","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1097\/IAE.0000000000001862","article-title":"Intravitreal aflibercept and ranibizumab injections for type 3 neovascularization","volume":"38","author":"Cho","year":"2018","journal-title":"Retina"},{"key":"R26-20250607","doi-asserted-by":"crossref","DOI":"10.1136\/bjophthalmol-2015-308074","article-title":"Short-term choroidal thickness changes in patients treated with either ranibizumab or aflibercept: a comparative study","author":"Kim","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"R27-20250607","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2019.08.023","article-title":"Macular atrophy in neovascular age-related macular degeneration: a randomized clinical trial comparing ranibizumab and aflibercept (RIVAL study)","author":"Gillies","year":"2020","journal-title":"Ophthalmology"},{"key":"R28-20250607","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(13)61501-9","article-title":"Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial","author":"Chakravarthy","year":"2013","journal-title":"Lancet"},{"key":"R29-20250607","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1167\/iovs.15-18837","article-title":"Geographic atrophy and activity of neovascularization in retinal angiomatous proliferation","volume":"57","author":"Baek","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R30-20250607","doi-asserted-by":"crossref","first-page":"1100.e1","DOI":"10.1016\/j.ajo.2015.02.020","article-title":"Progression of retinal pigment epithelial atrophy in antiangiogenic therapy of neovascular age-related macular degeneration","volume":"159","author":"Sch\u00fctze","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"R31-20250607","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.sjopt.2014.03.001","article-title":"Retention of good visual acuity in eyes with neovascular age-related macular degeneration and chronic refractory subfoveal subretinal fluid","volume":"28","author":"Bhavsar","year":"2014","journal-title":"Saudi J Ophthalmol"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003207","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T14:05:45Z","timestamp":1749305145000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003207"}},"subtitle":["A Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000003207","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]}}}